Iterion Therapeutics is a clinical-stage biotechnology company developing Tegavivint, a first-in-class novel targeted cancer therapeutic. Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/-catenin signaling pathway, which is implicated in cell proliferation, ...
Iterion Therapeutics is a clinical-stage biotechnology company developing Tegavivint, a first-in-class novel targeted cancer therapeutic. Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/-catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML) etc.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.